Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway [0.03%]
蛋白磷酸酶6通过mTORC1通路调节与代谢功能障碍相关的脂肪性肝炎
Zhengshuai Liu,Shuang Wei,Yang Jiang et al.
Zhengshuai Liu et al.
Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a serious chronic liver disease with limited therapies. Although fibroblast growth factor 21 (FGF21) analogs have shown promising therapeutic b...
Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability [0.03%]
揭开瞬时胰岛素抵抗的分子遗产：对肝代谢适应性的影响
Alexandre Berthier,Céline Gheeraert,Manjula Vinod et al.
Alexandre Berthier et al.
Background: Metabolic flexibility (MetF) is an organism's ability to adjust to changing metabolic supplies and energy demands. Insulin plays a central role in coordinating MetF through molecular mechanisms such as signali...
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH [0.03%]
MASH患者中FFAR1/FFAR4激动剂伊考布特的Ⅱb期随机对照试验
Stephen A Harrison,Naim Alkhouri,Grisell Ortiz-Lasanta et al.
Stephen A Harrison et al.
Background: Via regulation of glycemic control and inflammation, free fatty receptor (FFAR)1 and 4 are potential targets for the treatment of MASH. This study tested the efficacy and safety of icosabutate, a FFAR1/FFAR4 a...
Metabolic dysfunction-associated steatotic liver disease a multisystem disease: assessing the cost effectiveness of pharmacotherapies [0.03%]
与代谢功能异常相关的脂肪性肝病是一种多系统疾病：评估药物治疗的成本效益
Christopher D Byrne,Gregory J Dore
Christopher D Byrne
Reply to: "Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study" and "Optimal Timing To Initiate Antiviral Prophylaxis of MTCT: More Required to Be Done" [0.03%]
关于“优化抗病毒预防策略：一项真实世界研究的见解与反思”及“减少母婴传播的最佳抗病毒预防时机：任重道远”的回复
Mingwang Shen,Shihao He,Naijuan Yao et al.
Mingwang Shen et al.
Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B [0.03%]
2024年世卫组织慢性乙型肝炎治疗指南更新的覆盖范围
Jian Wang,Shaoqiu Zhang,Chuanwu Zhu et al.
Jian Wang et al.
Reply to: "Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective" [0.03%]
TDF致老年乙肝患者骨折风险评价的韩方视角——对《应用Thousand Chinese Patients Questionnaire调查慢性乙型肝炎治疗现状》的答复
Jimmy Che-To Lai,Jie Cai,Terry Cheuk-Fung Yip
Jimmy Che-To Lai
The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS [0.03%]
弗赖堡TIPS术后生存指数(FIPS)可判断TIPS术后进一步失代偿和ACLF的高风险患者
Lukas Sturm,Michael Schultheiss,Fabian Stöhr et al.
Lukas Sturm et al.
Background & aims: The Freiburg Index of Post-TIPS Survival (FIPS) defines a high-risk group of patients with significantly reduced survival following transjugular intrahepatic portosystemic shunt (TIPS) implantation. How...
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies [0.03%]
2014年至2023年丙型肝炎病毒治疗人数及新乙型肝炎和丁型肝炎治疗的适用经验教训
Homie A Razavi,Imam Waked,Huma Qureshi et al.
Homie A Razavi et al.
Background and aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally ar...